---
schema_version: "secwatch.filing_event.v1"
accession: "0000096943-25-000112"
form_type: "8-K"
ticker: "TFX"
cik: "0000096943"
company_name: "TELEFLEX INC"
filed_at: "2025-07-31T23:59:59+00:00"
generated_at: "2026-05-17T22:43:10.139580+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Teleflex Q2 adj. EPS $3.73 beats $3.42 YoY; raises FY outlook on BIOTRONIK deal

## Summary
- GAAP revenue $780.9M (+4.2% YoY); adjusted constant currency revenue growth +1.0%.
- GAAP diluted EPS $2.77 vs $1.69; adjusted diluted EPS $3.73 vs $3.42.
- Full-year GAAP revenue growth guidance raised to 9.0%-10.0% (from 1.3%-2.3%) due to BIOTRONIK acquisition.
- FY adjusted diluted EPS guidance raised to $13.90-$14.30 from $13.20-$13.60.
- Interventional segment revenue surged 20.4% as reported; OEM and Interventional Urology each declined over 8%.

## SEC filing metadata
- accession: 0000096943-25-000112
- form_type: 8-K
- ticker: TFX
- cik: 0000096943
- company_name: TELEFLEX INC
- filed_at: 2025-07-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/96943/000009694325000112/0000096943-25-000112-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/96943/000009694325000112/tfx-20250731.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000096943-25-000112
- JSON: https://secwatch.observer/filing/0000096943-25-000112.json
- Plain text: https://secwatch.observer/filing/0000096943-25-000112.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.